Franziska Guenther
Team Leader - Assay Development and Screening
Franziska earned her PhD in Neurophysiology from Friedrich-Alexander University of Erlangen-Nuernberg, in collaboration with King's College London, building on an academic background in Molecular Medicine and Cell & Molecular Biology.
From 2018, she spent five years as a postdoctoral scientist at the Alzheimer's Research UK Oxford Drug Discovery Institute (ODDI), where she developed assays for early-stage drug discovery.
She then spent two years in global innovation consulting, supporting research commercialisation, innovation interventions and implementation of policy frameworks.
In 2025, she returned to the ODDI to lead the Assay Development and Screening team, focusing on biochemical and biophysical high-throughput screening assays. Her team works to identify chemical compounds that validate novel targets in neurodegeneration and serve as potential leads for therapeutic development.
Franziska has a keen interest in the intersection of drug discovery and intellectual property law, particularly its impact on global medicine accessibility and interdisciplinary collaboration.
Recent publications
-
Structural Dynamics of the Ubiquitin Specific Protease USP30 in Complex with a Cyanopyrrolidine-Containing Covalent Inhibitor.
Journal article
O'Brien DP. et al, (2025), J Proteome Res, 24, 479 - 490
-
USP30 inhibition improves mitochondrial health through both PINK1-dependent and independent mechanisms
Preprint
Williamson MG. et al, (2025)
-
Structural Dynamics of the Ubiquitin Specific Protease USP30 in Complex with a Cyanopyrrolidine-Containing Covalent Inhibitor
Preprint
O’Brien DP. et al, (2024)